Growth hormone receptor polymorphism and growth hormone therapy response in children: A bayesian meta-analysis

American Journal of Epidemiology

Volumn 175, Issue 9, 2012, Pages 867-877

  Renehan, Andrew G ^a,b   Solomon, Mattea ^a   Zwahlen, Marcel ^c   Morjaria, Reena ^a   Whatmore, Andrew ^a   Audí, Laura ^d,e   Binder, Gerhard ^f   Blum, Werner ^g   Bougnres, Pierre ^h   Santos, Christine Dos ^h   Carrascosa, Antonio ^d,e   Hokken Koelega, Anita ⁱ   Jorge, Alexander ^j   Mullis, Primus E ^k   Tauber, Maïthé ^l   Patel, Leena ^a   Clayton, Peter E ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF BERN   (Switzerland)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g LILLY DEUTSCHLAND GMBH   (Germany)

^h HÔPITAL SAINT VINCENT DE PAUL   (France)

ⁱ SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^j UNIVERSITY OF SÃO PAULO   (Brazil)

^k UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^l HÔPITAL DES ENFANTS   (France)

more..

Author keywords

Bayesian meta analysis; genetic model; growth hormone; growth hormone receptor polymorphism

Indexed keywords

GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE;

CHILD; DATA SET; GENOTYPE; GROWTH REGULATOR; HERITABILITY; HORMONE; META-ANALYSIS; PHYSIOLOGICAL RESPONSE; POLYMORPHISM; RECOMBINATION; REGRESSION ANALYSIS;

BAYES THEOREM; CHILDHOOD DISEASE; DNA POLYMORPHISM; EMBASE; EXON; GENE DELETION; GENETIC VARIABILITY; GENOTYPE; GROWTH DISORDER; HORMONAL THERAPY; HUMAN; INHERITANCE; LONG TERM CARE; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW;

BAYES THEOREM; CARRIER PROTEINS; CHILD; GENETIC HETEROGENEITY; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; MODELS, GENETIC; POLYMORPHISM, GENETIC; PUBLICATION BIAS;

EID: 84860646129     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr408     Document Type: Review

References (53)

1. Bryant J, Baxter L, Cave CB, et al. Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst Rev. 2007;(3):CD004440. (doi:10.1002/14651858.CD004440.pub2).
2. Cuttler L, Silvers JB. Growth hormone treatment for idiopathic short stature: implications for practice and policy. Arch Pediatr Adolesc Med. 2004;158(2):108-110.
3. Ranke MB, Lindberg A. Predicting growth in response to growth hormone treatment. Growth Horm IGF Res. 2009; 19(1):1-11.
4. Lee JM, Davis MM, Clark SJ, et al. Estimated cost-effectiveness of growth hormone therapy for idiopathic short stature. Arch Pediatr Adolesc Med. 2006;160(3):263-269.
5. Bougnères P, Goffin V. The growth hormone receptor in growth. Endocrinol Metab Clin North Am. 2007;36(1):1-16.
6. Rosenfeld RG, Belgorosky A, Camacho-Hubner C, et al. Defects in growth hormone receptor signaling. Trends Endocrinol Metab. 2007;18(4):134-141.
7. Kelly PA, Goujon L, Sotiropoulos A, et al. The GH receptor and signal transduction. Horm Res. 1994;42(4-5):133-139.
8. Buzi F, Mella P, Pilotta A, et al. Growth hormone receptor polymorphisms. Endocr Dev. 2007;11:28-35. (doi:10.1159/000111055).
9. Sobrier ML, Duquesnoy P, Duriez B, et al. Expression and binding properties of two isoforms of the human growth hormone receptor. FEBS Lett. 1993;319(1-2):16-20.
10. Dos Santos C, Essioux L, Teinturier C, et al. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet. 2004;36(7):720-724.
11. Wassenaar MJ, Dekkers OM, Pereira AM, et al. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2009;94(10):3721-3730.
12. Bagos PG. A unification of multivariate methods for metaanalysis of genetic association studies. Stat Appl Genet Mol Biol. 2008;7(1). Article31. (doi:10.2202/1544-6115.1408).
13. Minelli C, Thompson JR, Abrams KR, et al. The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol. 2005;34(6):1319-1328.
14. Minelli C, Thompson JR, Abrams KR, et al. Bayesian implementation of a genetic model-free approach to the meta-analysis of genetic association studies. Stat Med. 2005;24(24):3845-3861.
15. Salanti G, Higgins JP. Meta-analysis of genetic association studies under different inheritance models using data reported as merged genotypes. Stat Med. 2008;27(5):764-777.
16. Ihara K, Hara T. Genetic polymorphisms in the growth hormone receptor: impact on growth response and disease susceptibility. Curr Pharmacogenomics Person Med. 2008;6(3):295-301.
17. Jorge AA, Arnhold IJ. Growth hormone receptor exon 3 isoforms and their implication in growth disorders and treatment. Horm Res. 2009;71(suppl 2):55-63.
18. Keni J, Cohen P. Optimizing growth hormone dosing in children with idiopathic short stature. Horm Res. 2009;71(suppl 1):70-74.
19. Cleves M. Hardy-Weinberg equilibrium test and allele frequency estimation. STB-48. Stata Tech Bull. 1999;8(48):280-284.
20. Salanti G, Southam L, Altshuler D, et al. Underlying genetic models of inheritance in established type 2 diabetes associations. Am J Epidemiol. 2009;170(5):537-545.
21. Speigelhalter D, Thomas A, Best N. WinBUGS User Manual Version 1.4.5 August 2009. Cambridge, United Kingdom: MRC Biostatistics Unit; 2009.
22. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172(1):137-159.
23. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? StatMed. 2002;21(11):1559-1573.
24. DerSimonianR,Laird N.Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
25. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
26. Harbord RM, Egger M, Sterne JA. A modified test for smallstudy effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443-3457.
27. Harbord RM, Harris RJ, Sterne JAC. Updated tests for bias in meta-analysis sbe196. Stata J. 2009SJ9-2.
28. BinderG, Baur F, Schweizer R, et al. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short smallfor-gestational-age children. J Clin Endocrinol Metab. 2006;91(2):659-664.
29. BlumWF,Machinis K, Shavrikova EP, et al. The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor. J Clin Endocrinol Metab. 2006;91(10):4171-4174.
30. Carrascosa A, Audí L, Esteban C, et al. Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH therapy in short small-for- gestational-age children. J Clin Endocrinol Metab. 2008;93(1):147-153.
31. Carrascosa A, Audí L, Fernández-Cancio M, et al. The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age. J Clin Endocrinol Metab. 2008;93(3):764-770.
32. Carrascosa A, Esteban C, Espadero R, et al. The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients. J Clin Endocrinol Metab. 2006;91(9): 3281-3286.
33. de Graaff LC, Meyer S, Els C, et al. GH receptor d3 polymorphism in Dutch patients with MPHD and IGHD born small or appropriate for gestational age. Clin Endocrinol (Oxf). 2008; 68(6):930-934.
34. Jorge AA, Marchisotti FG, Montenegro LR, et al. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency. J Clin Endocrinol Metab. 2006;91(3):1076-1080.
35. Ko JM, Kim JM, Cheon CK, et al. The common exon 3 polymorphism of the growth hormone receptor gene and the effect of growth hormone therapy on growth inKoreanpatientswithTurner syndrome. Clin Endocrinol (Oxf). 2010;72(2):196-202.
36. Räz B, JannerM, Petkovic V, et al. Influence of growth hormone (GH) receptor deletion of exon 3 and full-length isoforms onGH response and final height in patients with severe GH deficiency. J Clin Endocrinol Metab. 2008;93(3):974-980.
37. Solomon M, Morjaria R, Patel L, et al. Exon 3 deletion polymorphism of the growth hormone receptor (GHR) and GH response: a report of 97 cases (Manchester) and literature meta-analysis [abstract]. Growth Horm IGF Res. 2008; 18(suppl):S5-S6.
38. Tauber M, Ester W, Auriol F, et al. GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism. Clin Endocrinol (Oxf). 2007;67(3):457-461.
39. Wan L, Chen WC, Tsai Y, et al. Growth hormone (GH) receptor C.1319G>T polymorphism, but not exon 3 retention or deletion is associated with better first-year growth response to GH therapy in patients with GH deficiency. Pediatr Res. 2007; 62(6):735-740.
40. Audí L, Carrascosa A, Esteban C, et al. The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study. Spanish SGA Study Group. J Clin Endocrinol Metab. 2008;93(7):2709-2715.
41. Binder G, Trebar B, Baur F, et al. Homozygosity of the d3-growth hormone receptor polymorphism is associated with a high total effect of GH on growth and a low BMI in girls with Turner syndrome. Clin Endocrinol (Oxf). 2008;68(4):567-572.
42. Marchisotti FG, Jorge AA, Montenegro LR, et al. Comparison between weight-based and IGF-I-based growth hormone (GH) dosing in the treatment of children with GH deficiency and influence of exon 3 deleted GH receptor variant. Growth Horm IGF Res. 2009;19(2):179-186.
43. Drori-Herishanu L, Lodish M, Verma S, et al. The growth hormone receptor (GHR) polymorphism in growth-retarded children with Cushing disease: lack of association with growth and measures of the somatotropic axis. Horm Metab Res. 2010;42(3):194-197.
44. Ito Y, Makita Y, Matsuo K, et al. Influence of the exon 3 deleted isoform of GH receptor gene on growth response to GH in Japanese children [abstract]. Horm Res. 2005; 64(suppl 1):45.
45. Ko JM, Park JY, Yoo HW. Common exon 3 polymorphism of the GH receptor (GHR) gene and effect of GH therapy on growth in Korean children with idiopathic short stature (ISS). Clin Endocrinol (Oxf). 2009;70(1):82-87.
46. Jensen R, O'Connell S, Salgin B, et al. Insulin-like growth factor-I, d3-GHR polymorphism, prematurity and height at start as determinants of one year growth response during high dose GH; preliminary results from the NESGA Study (NESGAS) [abstract]. Horm Res. 2009;72(suppl 3):440.
47. Toyoshima MT, Castroneves LA, Costalonga EF, et al. Exon 3-deleted genotype of growth hormone receptor (GHRd3) positively influences IGF-1 increase at generation test in children with idiopathic short stature. Clin Endocrinol (Oxf). 2007;67(4):500-504.
48. Pilotta A, Mella P, Filisetti M, et al. Common polymorphisms of the growth hormone (GH) receptor do not correlate with the growth response to exogenous recombinant human GH in GH-deficient children. J Clin Endocrinol Metab. 2006; 91(3):1178-1180.
49. Pyathushkina G, Peterkova V. d3-GHR gene polymorphism and GH recombinant treatment efficacy in children with GH deficiency, Turner syndrome, and SGA [abstract]. Horm Res. 2007;68(suppl 1):166.
50. Darendeliler FF, Bas F, Bozkurt N, et al. The exon 3 deleted/full length growth hormone receptor polymorphism and response to GHtherapy in GH deficiency and Turner syndrome: amulticenter study [abstract]. Horm Res. 2009;72(suppl 3):109.
51. Bougnères P.The exon-3 deletion of the growth hormone receptor (GHR) gene still has a limited impact in clinical endocrinology. J Clin Endocrinol Metab. 2010;95(1):56-59.
52. Bakker B, Frane J, Anhalt H, et al. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. J Clin Endocrinol Metab. 2008;93(2):352-357.
53. RankeMB, Lindberg A,CowellCT, et al. Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database). JClinEndocrinolMetab. 2003;88(1):125-131.